Gastroparesis Drugs Market - Use of Gastroparesis Drugs Is Highest In North America, Owing To Increased Awareness about the Gastroparesis Condition and Heavy Expenditure by the Government on Healthcare, Followed By Europe and Asia-Pacific
Gastric paralysis affects the normal spontaneous movement of the gastrointestinal muscles and interferes with normal digestion, causing problems related to nausea, vomiting and blood sugar levels and nutrition. Gastroparesis can be caused by diabetes or after surgery. Recently, advanced drugs such as metoclopramide, erythromycin, and anti-vomiting have been developed to treat gastroparesis.
The major factors leading to the growth of the world market for peritoneal paroxysmal drugs are the number of surgeries that can lead to postoperative gastroparesis, increase in diabetic population, introduction of new drugs and increase in the elderly population. However, side effects associated with gastroparesis drugs and time-consuming regulatory approvals are expected to curb market growth. On the contrary, untapped market potential in emerging markets such as China and India and the development of new gastroparesis preventive drugs are expected to provide a good opportunity for market participants.
Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4153
The list of key players profiled in this report include
• Allergan Plc.
• Abbott Laboratories (Abbott Arzneimittel GmbH)
• AstraZeneca Plc.
• Cadila Pharmaceuticals Ltd.
• ETX Pharma Inc
• Evoke Pharma
• GlaxoSmithKline Plc.
• Neurogastrx Inc.
• Valeant Pharmaceuticals International Inc.
• Theravance Biopharma.
Key players in the value chain include Altos Therapeutics LLC, Mylan N.V., Hexal AG, CEVA Group PLC, and Takeda Pharmaceutical Company Ltd.
The prokinetic agents segment occupied the largest share in 2016, owing to the high usage, applicability, and availability of prokinetic agents for treating gastroparesis. Furthermore, the botulinum toxin injection segment is expected to grow at the highest CAGR of 5.6% from 2017 to 2023, and is anticipated to continue its dominance during the forecast period.
The utilization rate of gastroparesis drugs for idiopathic gastroparesis is high, however post-surgical gastroparesis segment is expected to grow at a CAGR of 5.2% during the forecast period. This is attributed to increase in incidence of various types of surgeries, such as transplantation, which result in postsurgical gastroparesis.
Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/4153
Key findings of the Gastroparesis Drugs Market:
• Prokinetic agents segment accounted for more than four-fifths share of the global gastroparesis drugs market in 2016.
• Botulinum toxin injection segment is expected to grow at a CAGR of 5.6% from 2017 to 2023.
• Idiopathic gastroparesis segment accounted for around 34.9% share of the global gastroparesis drugs market in 2016.
• Hospitals accounted for nearly two-fifths share of the global gastroparesis drugs market in 2016.
• Pharmacies segment is expected to grow at a CAGR of 5.0% from 2017 to 2023
North America was the leading revenue contributor to the global gastroparesis drugs market, accounting for nearly one-third of the global market. This is attributed to the early approval of gastroparesis drugs and high use of these drugs due to rise in incidence of gastroparesis. However, Asia-Pacific is expected to grow at the highest CAGR of 5.5% during the study period, due to increase in affordability, surge in healthcare expenditure, and rise in awareness toward gastroparesis drugs.
Access Full Summery @ https://www.alliedmarketresearch.com/gastroparesis-drugs-market
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gastroparesis Drugs Market - Use of Gastroparesis Drugs Is Highest In North America, Owing To Increased Awareness about the Gastroparesis Condition and Heavy Expenditure by the Government on Healthcare, Followed By Europe and Asia-Pacific here
News-ID: 1606146 • Views: 346
More Releases from Allied Market Research
North America Geogrid Market 2020 Segmentation, Demand, Growth, Trend, Opportuni …
According to the report published by Allied Market Research, the North America geogrid market generated $282.0 million in 2019, and is estimated to reach $408.25 million by 2027, registering a CAGR of 7.0% from 2020 to 2027. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios. Surge in infrastructure development activities across the U.S. and Mexico and superior physical properties
Intravenous Immunoglobulin (IVIG) Market 2020 In-Depth Analysis of Industry Shar …
Global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds
Asthma and COPD Drugs Market Is Expected to Witness a Steady Growth by 2026
"Asthma and COPD Drugs Market by Disease and Medication Class - Global Opportunity Analysis and Industry Forecasts, 2014-2022", projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America
Synthetic Biology Market in Global Industry by Top Companies, Type and Applicati …
Global Synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020). Europe occupies largest share in the global market and would hold-on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014 - 2020. Read Full Report @ https://www.alliedmarketresearch.com/synthetic-biology-market Synthetic biology is at a nascent stage and has recently
More Releases for Gastroparesis
Diabetic Gastroparesis Industry Analysis, Study And Pipeline Review H2 2017
Overview Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss
Diabetic Gastroparesis-Pipeline Review H1 2017
ReportsWeb.com has announced the addition of the “Diabetic Gastroparesis-Pipeline Review H1 2017” this report provides an overview of the Diabetic Gastroparesis-Pipeline landscape. Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2017, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape. Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts
Diabetic Gastroparesis - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Diabetic Gastroparesis - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H2 2017, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape. Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels
Gastroparesis Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, Gastroparesis Global Clinical Trials Review, H2, 2017" provides an overview of Gastroparesis clinical trials scenario. This report provides top line data relating to the clinical trials on Gastroparesis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status
Diabetic Gastroparesis - Pipeline Market Research Report, 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Diabetic Gastroparesis - Pipeline Insight, 2017”. This report provides comprehensive insights about pipeline drugs across this Diabetic Gastroparesis. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Diabetic Gastroparesis. Request For Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1214082 This report provides information on the therapeutic development for
Global Diabetes Gastroparesis Market Key Trends & Industry Forecast 2017 - 2025
Diabetes type 1 and type 2 are one of the most common chronic diseases prevalent in the world, affecting millions of people. One of the disorders associated with diabetes type 1 and type 2 is gastroparesis, which is characterized by the delayed emptying of the stomach. One of the major causes of gastroparesis is damage to the vagus nerve, reducing the mobility of the stomach contents. Diabetic neuropathy affects the